Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This study found that ChatGPT 4.0 and Gemini 1.5 Flash provided more accurate and user-friendly responses to androgenetic alopecia questions than Deepseek R1, suggesting they could be effective tools for patient education with physician guidance.

This article discusses the discontinuation of the Bexxar regimen for non-Hodgkin's lymphoma, noting that despite its effectiveness, it was under-prescribed due to marketing and development challenges without reporting new clinical results.

In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.

This study developed and validated a precise RP-HPLC method for simultaneously estimating minoxidil and aminexil in pharmaceutical formulations with good accuracy and specificity.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

This study reports that the dye peri-xanthenoxanthene (PXX) can act as an efficient photocatalyst for various radical reactions, including complex dual catalytic processes and the synthesis of an investigational drug intermediate.

Endoxan often causes hair loss, which usually starts in the third week of treatment.

The excimer laser may help hair regrow in alopecia areata patients.

This study suggests that using antihistamines alongside a regimen of topical corticosteroid and superficial cryotherapy may enhance hair regrowth in patients with mild to moderate alopecia areata.

This abstract provides no new clinical results; it discusses the role of surgery and interventional radiotherapy in treating cutaneous squamous cell carcinoma.

In this study, researchers used conditional mouse models to show that inactivation of the Alx4 gene in specific cell lineages leads to craniofacial and limb defects without affecting postnatal survival, providing insights into Alx4's role in development and disease.

This study developed a consensus document to guide danazol discontinuation in hereditary angioedema patients, enhancing the standardization and safety of treatment protocols.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

This study found that pentoxifylline plus topical corticosteroids had the highest treatment success rate for alopecia areata compared to no treatment, but the best overall treatment remains uncertain due to varying data.

This website listing states that casemedicalresearch.com is available for purchase and aims to offer comprehensive information on various topics, highlighting it as a potential resource.

This study reported that among 10 tested 2-(4-chlorophenyl)-5-aryl-1,3,4-oxadiazole compounds, compound 4c showed the highest activity against cancer cell lines, with a 95.37% average growth rate.

This review discusses the state-of-the-art knowledge on pseudoxanthoma elasticum, summarizing recent advancements in genetics, pathomechanisms, and potential treatments but reports no new clinical findings.

This study confirms that twice-daily application of 5% minoxidil solution, Carexidil®, is effective for androgenetic alopecia in both men and women, showing results after 6 months.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

This research highlights the potential of using nanomaterials with advanced reactive oxygen properties to target oxidative stress in hair follicle tissue, which is associated with androgenetic alopecia, addressing a gap in the current understanding of AGA treatments.

This study used a multi-layer in silico framework to evaluate Korean herbal compounds for androgenetic alopecia, identifying Biochanin A, Saponin Re, and Emodin as potential topical candidates with distinct safety and affinity profiles, although these findings remain purely computational without experimental validation.

The researchers reported that QR678 Neo® combined with intralesional steroids significantly improved hair regrowth and patient satisfaction in treating alopecia areata compared to steroids alone.

This review discusses emerging evidence on azathioprine's efficacy and safety for severe alopecia areata, reporting sustained response in many patients but emphasizing the need for controlled trials.

In a case-series study, researchers reported significant hair regrowth in Alopecia Areata patients after three months of treatment with a topical preparation called Freezia cream, which was developed by specialized medical professionals and approved by the Iraqi Ministry of Health.